共 50 条
- [41] Complete response using the EZH2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phaseINTERNATIONAL CANCER CONFERENCE JOURNAL, 2024, 13 (04): : 488 - 492Kikuchi, ShoheiNabe, YoshimiHoraguchi, RyusukeMinemura, TomokiMurakami, JunNoguchi, AkiraTakagi, KohjiKamihara, YusukeWada, AkinoriFujihira, TakumaSato, Tsutomu
- [42] Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignanciesSignal Transduction and Targeted Therapy, 8Husheng MeiHong WuJing YangBin ZhouAoli WangChen HuShuang QiZongru JiangFengming ZouBeilei WangFeiyang LiuYongfei ChenWenchao WangJing LiuQingsong Liu
- [43] Selective killing of SMARCA2-and SMARCA4-deficient tumors by inhibition of EZH2: In vitro and in vivo preclinical modelsCANCER RESEARCH, 2017, 77Chan-Penebre, ElayneArmstrong, KelliDrew, AllisonGrassian, Alexandra R.Feldman, IgorRoche, MariaHo, PeterBrach, DorothyRaimondi, AlejandraCopeland, Robert A.Chesworth, RichardSmith, Jesse J.Ribich, Scott A.
- [44] Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor proteinNature Communications, 12Brajendra K. TripathiMeghan F. AndermanDisha BhargavaLuciarita BoccuzziXiaolan QianDunrui WangMarian E. DurkinAlex G. PapageorgeFernando J. de MiguelKaterina PolitiKylie J. WaltersJames H. DoroshowDouglas R. Lowy
- [45] Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor proteinNATURE COMMUNICATIONS, 2021, 12 (01)Tripathi, Brajendra K.Anderman, Meghan F.Bhargava, DishaBoccuzzi, LuciaritaQian, XiaolanWang, DunruiDurkin, Marian E.Papageorge, Alex G.de Miguel, Fernando J.Politi, KaterinaWalters, Kylie J.Doroshow, James H.Lowy, Douglas R.
- [46] Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing ProgramPEDIATRIC BLOOD & CANCER, 2017, 64 (03)Kurmasheva, Raushan T.Sammons, MelissaFavours, EdwardWu, JianwrongKurmashev, DiasCosmopoulos, KatherineKeilhack, HeikeKlaus, Christine R.Houghton, Peter J.Smith, Malcolm A.
- [47] Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Li, Xiao-NanQi, LinKogiso, MariLindsay, Holly BrianneErickson, Stephen W.Guo, YuelongSmith, Malcolm A.Teicher, Beverly A.
- [48] A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsNature Chemical Biology, 2012, 8 : 890 - 896Sarah K KnutsonTim J WigleNatalie M WarholicChristopher J SneeringerChristina J AllainChristine R KlausJoelle D SacksAlejandra RaimondiChristina R MajerJeffrey SongMargaret Porter ScottLei JinJesse J SmithEdward J OlhavaRichard ChesworthMikel P MoyerVictoria M RichonRobert A CopelandHeike KeilhackRoy M PollockKevin W Kuntz
- [49] A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsNATURE CHEMICAL BIOLOGY, 2012, 8 (11) : 890 - 896Knutson, Sarah K.Wigle, Tim J.Warholic, Natalie M.Sneeringer, Christopher J.Allain, Christina J.Klaus, Christine R.Sacks, Joelle D.Raimondi, AlejandraMajer, Christina R.Song, JeffreyScott, Margaret PorterJin, LeiSmith, Jesse J.Olhava, Edward J.Chesworth, RichardMoyer, Mikel P.Richon, Victoria M.Copeland, Robert A.Keilhack, HeikePollock, Roy M.Kuntz, Kevin W.
- [50] PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumorsPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (46) : 12249 - 12254Januario, ThomasYe, XiaofenBainer, RussellAlicke, BrunoSmith, TundeHaley, BenjaminModrusan, ZoraGould, StephenYauch, Robert L.